ThermoGenesis Holdings, Inc., formerly Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It offers a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Its CAR-TXpress platform is its cellular processing platform. It offers cell manufacturing tools and services in the global cell and gene therapy market.